vs

Side-by-side financial comparison of IONIS PHARMACEUTICALS INC (IONS) and POTLATCHDELTIC CORP (PCH). Click either name above to swap in a different company.

POTLATCHDELTIC CORP is the larger business by last-quarter revenue ($314.2M vs $203.3M, roughly 1.5× IONIS PHARMACEUTICALS INC). POTLATCHDELTIC CORP runs the higher net margin — 8.2% vs -112.8%, a 121.1% gap on every dollar of revenue. On growth, POTLATCHDELTIC CORP posted the faster year-over-year revenue change (23.1% vs -10.3%). POTLATCHDELTIC CORP produced more free cash flow last quarter ($50.1M vs $-159.0M). Over the past eight quarters, IONIS PHARMACEUTICALS INC's revenue compounded faster (30.4% CAGR vs 11.1%).

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.

IONS vs PCH — Head-to-Head

Bigger by revenue
PCH
PCH
1.5× larger
PCH
$314.2M
$203.3M
IONS
Growing faster (revenue YoY)
PCH
PCH
+33.4% gap
PCH
23.1%
-10.3%
IONS
Higher net margin
PCH
PCH
121.1% more per $
PCH
8.2%
-112.8%
IONS
More free cash flow
PCH
PCH
$209.1M more FCF
PCH
$50.1M
$-159.0M
IONS
Faster 2-yr revenue CAGR
IONS
IONS
Annualised
IONS
30.4%
11.1%
PCH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IONS
IONS
PCH
PCH
Revenue
$203.3M
$314.2M
Net Profit
$-229.4M
$25.9M
Gross Margin
96.1%
18.2%
Operating Margin
-105.5%
11.2%
Net Margin
-112.8%
8.2%
Revenue YoY
-10.3%
23.1%
Net Profit YoY
-119.8%
682.5%
EPS (diluted)
$-1.35
$0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IONS
IONS
PCH
PCH
Q4 25
$203.3M
Q3 25
$156.7M
$314.2M
Q2 25
$452.0M
$275.0M
Q1 25
$131.6M
$268.3M
Q4 24
$226.6M
$258.1M
Q3 24
$133.8M
$255.1M
Q2 24
$225.3M
$320.7M
Q1 24
$119.5M
$228.1M
Net Profit
IONS
IONS
PCH
PCH
Q4 25
$-229.4M
Q3 25
$-128.6M
$25.9M
Q2 25
$123.6M
$7.4M
Q1 25
$-146.9M
$25.8M
Q4 24
$-104.3M
$5.2M
Q3 24
$-140.5M
$3.3M
Q2 24
$-66.3M
$13.7M
Q1 24
$-142.8M
$-305.0K
Gross Margin
IONS
IONS
PCH
PCH
Q4 25
96.1%
Q3 25
98.5%
18.2%
Q2 25
99.1%
13.0%
Q1 25
98.9%
17.8%
Q4 24
98.3%
13.4%
Q3 24
99.2%
10.8%
Q2 24
98.2%
11.9%
Q1 24
98.2%
7.0%
Operating Margin
IONS
IONS
PCH
PCH
Q4 25
-105.5%
Q3 25
-102.2%
11.2%
Q2 25
30.9%
5.0%
Q1 25
-111.6%
10.3%
Q4 24
-48.9%
5.2%
Q3 24
-111.1%
2.8%
Q2 24
-29.3%
5.4%
Q1 24
-125.1%
-2.1%
Net Margin
IONS
IONS
PCH
PCH
Q4 25
-112.8%
Q3 25
-82.1%
8.2%
Q2 25
27.3%
2.7%
Q1 25
-111.6%
9.6%
Q4 24
-46.1%
2.0%
Q3 24
-105.0%
1.3%
Q2 24
-29.4%
4.3%
Q1 24
-119.5%
-0.1%
EPS (diluted)
IONS
IONS
PCH
PCH
Q4 25
$-1.35
Q3 25
$-0.80
$0.33
Q2 25
$0.70
$0.09
Q1 25
$-0.93
$0.33
Q4 24
$-0.66
$0.07
Q3 24
$-0.95
$0.04
Q2 24
$-0.45
$0.17
Q1 24
$-0.98
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IONS
IONS
PCH
PCH
Cash + ST InvestmentsLiquidity on hand
$2.7B
$88.8M
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$489.1M
$1.9B
Total Assets
$3.5B
$3.2B
Debt / EquityLower = less leverage
3.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IONS
IONS
PCH
PCH
Q4 25
$2.7B
Q3 25
$2.2B
$88.8M
Q2 25
$2.3B
$95.3M
Q1 25
$2.1B
$147.5M
Q4 24
$2.3B
$151.6M
Q3 24
$2.5B
$161.1M
Q2 24
$2.1B
$199.7M
Q1 24
$2.2B
$180.2M
Total Debt
IONS
IONS
PCH
PCH
Q4 25
$1.8B
Q3 25
Q2 25
Q1 25
Q4 24
$1.3B
$1.0B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IONS
IONS
PCH
PCH
Q4 25
$489.1M
Q3 25
$618.0M
$1.9B
Q2 25
$631.7M
$1.9B
Q1 25
$475.7M
$2.0B
Q4 24
$588.4M
$2.0B
Q3 24
$662.5M
$2.1B
Q2 24
$263.7M
$2.1B
Q1 24
$296.5M
$2.2B
Total Assets
IONS
IONS
PCH
PCH
Q4 25
$3.5B
Q3 25
$3.0B
$3.2B
Q2 25
$3.0B
$3.2B
Q1 25
$2.8B
$3.3B
Q4 24
$3.0B
$3.3B
Q3 24
$3.1B
$3.3B
Q2 24
$2.7B
$3.4B
Q1 24
$2.8B
$3.4B
Debt / Equity
IONS
IONS
PCH
PCH
Q4 25
3.71×
Q3 25
Q2 25
Q1 25
Q4 24
2.13×
0.51×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IONS
IONS
PCH
PCH
Operating Cash FlowLast quarter
$-137.7M
$65.7M
Free Cash FlowOCF − Capex
$-159.0M
$50.1M
FCF MarginFCF / Revenue
-78.2%
15.9%
Capex IntensityCapex / Revenue
10.5%
4.9%
Cash ConversionOCF / Net Profit
2.54×
TTM Free Cash FlowTrailing 4 quarters
$-320.0M
$132.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IONS
IONS
PCH
PCH
Q4 25
$-137.7M
Q3 25
$-131.4M
$65.7M
Q2 25
$151.3M
$41.0M
Q1 25
$-150.8M
$49.1M
Q4 24
$-116.1M
$45.4M
Q3 24
$-115.0M
$26.5M
Q2 24
$-119.9M
$100.6M
Q1 24
$-149.9M
$16.0M
Free Cash Flow
IONS
IONS
PCH
PCH
Q4 25
$-159.0M
Q3 25
$-136.7M
$50.1M
Q2 25
$139.0M
$30.6M
Q1 25
$-163.4M
$26.3M
Q4 24
$-141.6M
$25.4M
Q3 24
$-124.0M
$-8.2M
Q2 24
$-126.1M
$72.4M
Q1 24
$-154.4M
$2.0M
FCF Margin
IONS
IONS
PCH
PCH
Q4 25
-78.2%
Q3 25
-87.2%
15.9%
Q2 25
30.8%
11.1%
Q1 25
-124.1%
9.8%
Q4 24
-62.5%
9.9%
Q3 24
-92.7%
-3.2%
Q2 24
-56.0%
22.6%
Q1 24
-129.2%
0.9%
Capex Intensity
IONS
IONS
PCH
PCH
Q4 25
10.5%
Q3 25
3.4%
4.9%
Q2 25
2.7%
3.8%
Q1 25
9.6%
8.5%
Q4 24
11.3%
7.7%
Q3 24
6.8%
13.6%
Q2 24
2.8%
8.8%
Q1 24
3.8%
6.1%
Cash Conversion
IONS
IONS
PCH
PCH
Q4 25
Q3 25
2.54×
Q2 25
1.22×
5.58×
Q1 25
1.90×
Q4 24
8.74×
Q3 24
7.99×
Q2 24
7.35×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IONS
IONS

Products$58.0M29%
Spinraza Royalties$54.0M27%
Collaborative Agreement Revenue$52.4M26%
Wainus Royalties$16.0M8%
Wainua Joint Development Revenue$9.6M5%
Other Commercial$7.6M4%
Other Royalties$5.7M3%

PCH
PCH

Lumber$131.8M42%
Timberlands$52.5M17%
Rural Real Estate$51.3M16%
Residuals And Panels$34.0M11%
Pulpwood$16.7M5%
Development Real Estate$14.6M5%
Other$8.1M3%
Other Products$5.2M2%

Related Comparisons